Tricida Inc

Tricida — Investor Presentation (January 2022)

33 slides from Tricida's investor presentation, Jan 10, 2022

  1. Slide 1: Slowing the Progression of Chronic Kidney Disease: Tricida Investor Presentation

    Slowing the Progression of Chronic Kidney Disease Tricida Investor Presentation January 2022 Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements Any statements contained in this presentation or made during the accompanying oral presentation that are not statements of historical facts are forward-looking statements as defined under the Federal securities laws. Examples of such statements include our plans, beliefs

  3. Slide 3: Tricida Highlights

    3 Tricida Highlights • The Unmet Need – Acid-base balance and retained acid fundamentally impact kidney disease • The In-House Discovered Compound – Veverimer could be the first and only therapy to slow CKD progression through binding and removing retained acid • The Outcomes Trial – VALOR-CKD is a

  4. Slide 4: The Unmet Need

    The Unmet Need There are no FDA-approved therapies to slow CKD progression through the treatment of metabolic acidosis in patients with CKD

  5. Slide 5: Kidney Disease Impacts Acid-Base Balance

    5 Daily Metabolism Kidney Disease Impacts Acid-Base Balance Which Is Critical to Maintain Normal Physiologic Function Kraut. Nat Rev Nephrol. 2010;6(5):274; KDIGO Clinical Practice Guidelines 2012. Diseased Kidneys Lose Capacity to Excrete Acid Acid is generated from dietary sources and daily metabo

  6. Slide 6: Persistent Acid Retention and Sustained Expression of ET-1, Aldosterone and Angiotensin

    6 Laghmani K et al., J Clin Invest 107:1563-9, 2001. Wesson DE, J Am Soc Nephrol 12:1826-35, 2001. Wesson DE et al., Kidney Int 78:1128-35, 2010. Wesson DE et al., Kidney Int 82:1184-94, 2012. Wesson DE et al., Nephrol Dial Transplant 30:762-70, 2015. Phisitkul S et al., Kidney Int 77:617-23, 2010.

  7. Slide 7: Retained Acid Results in Muscle Wasting and Bone Demineralization

    7 Retained Acid Results in Muscle Wasting and Bone Demineralization Kraut 2017; Raphael 2018; Wang 2014; Rajan 2008; Stitt 2004; Amodu 2016; Kestenbaum 2020. Figure adapted from Kraut 2017. Bone DemineralizationMuscle Wasting Acid Retention Systemic pHMuscle pH Pro-Inflammatory Cytokines Insulin / I

  8. Slide 8: Persistent Acid Retention Can Result in Serious Health Consequences

    8 Persistent Acid Retention Can Potentially Result in Serious Health Consequences Acid Buffering Leads to Increased Protein Catabolism Muscle Wasting, Reduced Physical Functioning Acid Buffering Leads to Loss of Bone Density Increased Risk of Fractures, Renal Osteodystrophy Reduced Renal Acid Secret

  9. Slide 9: No FDA-Approved Therapies to Slow CKD Progression Through Treating Metabolic Acidosis

    9 Despite the High Unmet Need, There Are No FDA-Approved Therapies to Slow CKD Progression Through the Treatment of Chronic Metabolic Acidosis * Represents patients with Stages 1-5 CKD and metabolic acidosis. Data on file: 2019 US Census data, USRDS 2020 Annual Report, KDIGO 2012, Inker 2011. ** Bas

  10. Slide 10: Prevalence of Metabolic Acidosis in CKD and Patients Treated by Physician Type

    10 Prevalence of Metabolic Acidosis in Patients with CKD and Estimated Number of Patients Treated by Physician Type Focus on nephrologist-treated patients provides initial opportunity for veverimer Expansion to non-nephrologist- treated patients provides additional opportunity for veverimer Increase

  11. Slide 11: Veverimer Potential First FDA-Approved Therapy for Metabolic Acidosis and CKD Progression

    Veverimer has the potential to be the first and only FDA-approved therapy to treat metabolic acidosis and slow CKD progression

  12. Slide 12: Veverimer: Designed to Bind and Remove Hydrochloric Acid

    12GI: Gastrointestinal. HCl: Hydrochloric acid. *Veverimer’s maximum theoretical HCl binding capacity is approximately 10 mEq/gram. Excreted, resulting in removal of HCl* Binds protons (H+) and then selectively binds chloride (Cl–) in the GI tract Excretion in Feces O ra l I ng es tio n Ac id B in d

  13. Slide 13: Veverimer Was Designed to Bind and Remove Acid in Patients with CKD

    13 Veverimer Was Designed to Bind and Remove Acid in Patients with CKD Wesson DE, CJASN, 2021. Alpern RJ and Sakhaee K, AJKD, 1997. Klaerner G et al, J Pharmacol Exp Ther. 2020. Wesson DE et al, Lancet, 2019 Acid-Base Balance Is Impaired When Kidneys Are Unable to Fully Excrete Acid Load Veverimer B

  14. Slide 14: Veverimer Clinical Development Program

    14 Veverimer Clinical Development Program * Bushinsky 2018. **Wesson 2019. ***Wesson 2019. Completed Clinical Trials TRCA-101* 2-week, randomized, double-blind, placebo-controlled Phase 1/2 trial • 3 doses and 2 dosing regimens of veverimer or placebo • Blood bicarbonate endpoint • 135 subjects TRCA

  15. Slide 15: TRCA-301 Serum Bicarbonate Increase and Time-to-Event Analyses

    15 TRCA-301 Veverimer-Treated Subjects Experienced a Mean Increase from Baseline in Serum Bicarbonate of 4.5 mEq/L Tricida’s TRCA-301/301E Clinical Trials Have Advanced the Understanding of Metabolic Acidosis Veverimer is not yet approved by the FDA. BL: Baseline. W: Week. Error bars: Standard error

  16. Slide 16: Summary of Past FDA Interactions and Goals for NDA Resubmission

    16 Summary of Past FDA Interactions and Our Goals for Potential Resubmission of the Veverimer NDA • Submitted NDA for review through the Accelerated Approval Program • Received CRL August 2020 • Held End-of-Review Type A meeting with FDA Division of Cardiology and Nephrology October 2020 • Submitted

  17. Slide 17: The VALOR-CKD Trial Design

    The VALOR-CKD trial is designed to evaluate whether veverimer slows CKD progression in patients with metabolic acidosis and CKD

  18. Slide 18: 2022 Focus: Execution and Completion of the VALOR-CKD Renal Outcomes Trial

    18 2022 Focus: Execution and Completion of the VALOR-CKD Renal Outcomes Trial • Time-to-event, multicenter, randomized, double-blind, placebo-controlled trial • Primary endpoint: DD40, defined as time to first occurrence of renal death, ESRD or a confirmed ≥ 40% reduction in eGFR Veverimer QD (n~740

  19. Slide 19: Tricida Will Gain Significant Information from the VALOR-CKD Trial

    19 DD40 = renal death, end stage renal disease (ESRD), or ≥ 40% reduction in estimated glomerular filtration (eGFR). DD50 = death, ESRD, or ≥ 50% reduction in eGFR. KDQOL = kidney disease quality of life. CV = Cardiovascular. DXA = dual x-ray absorptometry. Tricida Will Gain Significant Information

  20. Slide 20: Making Good Progress in Conducting our VALOR-CKD Renal Outcomes Trial

    20 Making Good Progress in Conducting our VALOR-CKD Renal Outcomes Trial As of January 6, 2022, the VALOR-CKD trial has randomized over 1,480 subjects with an average treatment duration of ~21 months and has accrued 183 subjects with positively adjudicated primary endpoint events (renal death, ESRD,

  21. Slide 21: VALOR-CKD Primary Endpoint Events Continue to Accrue on Track

    21 VALOR-CKD Primary Endpoint Events Continue to Accrue on Track 183 Subjects with Primary Endpoint Events as of January 6, 2022 24 Additional Events Since the November 5, 2021, Third Quarter Financial Results Call Source: Inker et al. JASN 30:1735-1745, 2019, Data on event rates among 2197 control

  22. Slide 22: VALOR-CKD Outlook for 2022

    22 VALOR-CKD Outlook for 2022 * Refer to page 25 for powering assumptions. • Based on its financial runway, Tricida plans to stop the VALOR-CKD trial for administrative reasons in 2022 – Plan to stop prior to reaching the protocol specified 511 subjects with primary endpoint events – Now anticipate

  23. Slide 23: Multiple Studies Show Treating Acid Retention Can Slow CKD Progression

    23 Multiple Studies Have Provided Solid Evidence that Treating Acid Retention Can Slow CKD Progression

  24. Slide 24: Key Findings from Studies on Treating Metabolic Acidosis to Slow CKD Progression

    24 Key Findings from a Review of Studies Designed to Slow CKD Progression Through the Treatment of Metabolic Acidosis Author Lower Risk of CKD Progression Hazard Ratio de Brito-Ashurst, 2009 80% 0.20 Garneata, 2016 69% 0.31 Dubey, 2020 51% 0.49 Goraya and Wesson 2019. Limitations of these studies in

  25. Slide 25: Powering Assumptions and Observed Hazard Ratios for Administrative Stop

    25 Powering Assumptions and Observed Hazard Ratios for Stopping the VALOR-CKD Trial for Administrative Reasons True Hazard Ratio Administrative Stop at: 200 Events* 250 Events* 0.76 47% Power 56% Power 0.70 69% Power 78% Power 0.60 94% Power 97% Power 0.50 >99% Power >99% Power Observed hazard ratio

  26. Slide 26: Positive VALOR-CKD Data Could Support NDA Re-submission and Expanded Program

    Positive VALOR-CKD data has the potential to support an NDA re-submission and enable an expanded veverimer development program

  27. Slide 27: Tricida Future Milestones and Potential NDA Resubmission

    27 If positive, VALOR-CKD trial results could lead to a possible resubmission of the veverimer NDA with an anticipated 6-month review 4Q Tricida plans to initiate an administrative stop of the VALOR-CKD trial 3Q1Q Tricida Future Milestones 2Q 2022 Milestones 2023 Potential Milestones Anticipate repo

  28. Slide 28: Positive VALOR-CKD Data Could Support an Expanded Veverimer Development Program

    28 Positive VALOR-CKD Data Has the Potential to Support an Expanded Veverimer Development Program By the time a patient exhibits overt metabolic acidosis (i.e., serum bicarbonate levels < 22 mEq/L), damage from retained acid has already occurred. Treatment of retained acid with veverimer prior to ov

  29. Slide 29: Clinical Development Strategy and Significant Opportunity in CKD

    29 VALOR-CKD Ongoing trial Study inclusion: eGFR 20 to 40 and SBC 12 to 20 mEq/L VICTORY-CKD Future trial Study inclusion: eGFR 20 to 60 and SBC 12 to 24 mEq/L TRIUMPH-CKD Future trial Study inclusion: eGFR <90 and SBC <27 mEq/L SBC = serum bicarbonate. Source: Data on file. 2019 US Census data, USR

  30. Slide 30: Robust Patent Portfolio for Veverimer Provides Protection Until 2038

    30 • Several pending patent applications United States • Three issued EPO patents providing patent protection until 2034 and two issued patents providing protection until 2035 • Several pending EPO patent applications Europe Rest of World • Issued patents provide protection in numerous countries/reg

  31. Slide 31: Financial Position

    31 Financial Position • ~ $150.6 million cash, cash equivalents and investments as of December 31, 2021* • Debt includes $200 million of 3.50% Convertible Senior Notes due 2027 • ~ 55.4 million total shares outstanding as of December 31, 2021** * Unaudited. Anticipate reporting full Q4 2021 financia

  32. Slide 32: Tricida Highlights

    32 Tricida Highlights • The Unmet Need – Acid-base balance and retained acid fundamentally impact kidney disease – Significant opportunity to treat up to 4.3 million patients with metabolic acidosis and CKD in the US – Future opportunities based on the need for removal of retained acid in patients w

  33. Slide 33: Thank You

    THANK YOU Tricida Investor Presentation January 2022

Tricida — Investor Presentation (January 2022) on 6ix